跳至主導覽 跳至搜尋 跳過主要內容

The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy

  • Yao Ren Yang
  • , Chung Sheng Shi
  • , Sheng Wei Chang
  • , Yu Ying Wu
  • , Yu Li Su
  • , Geng Ping Lin
  • , Feng Che Kuan*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

7 引文 斯高帕斯(Scopus)

摘要

Sarcopenia has been associated with conventional chemotherapy-related toxicity, postoperative complications and poor overall survival in patients with genotype-unselected metastatic colorectal cancer (mCRC). This study aimed to evaluate the prognostic implications of sarcopenia and its change after perioperative cetuximab plus doublet chemotherapy and hepatectomy in patients with RAS wild-type colorectal liver metastasis (CRLM). Patients with CRLM from 2007 to 2018 in Chang Gung Research Database were retrospectively analyzed. Baseline characteristics as well as skeletal muscle index (SMI) at baseline and dynamic changes after interventions were collected. A multivariate Cox proportional hazard model was used to evaluate the effect of each parameter on overall survival (OS), and the Kaplan–Meier method was used to establish survival curves. A two-sided p value < 0.05 was considered statistically significance. Of 214 RAS wild-type mCRC patients who received both cetuximab and doublet chemotherapy, 77 who received upfront or subsequent hepatectomy were included in this study. The median follow-up time was 2.3 years. The rate of sarcopenia was higher in the patients who received neoadjuvant cetuximab-containing regimens than in those who received upfront hepatectomy (95% versus 63%, p = 0.001). Increased SMI after perioperative systemic therapy remained independently associated with better OS in multivariate analysis [hazard ratio (HR) = 0.27/10% increase, p = 0.013). The patients with sarcopenia had a trend of worse OS than those without sarcopenia (median OS: 4.5 versus 3.6 years, log-rank p = 0.282). Improvement in sarcopenia ([SMI after intervention − initial SMI]/initial SMI × 100%) is an important prognostic factor for OS. Future research is warranted to investigate direct interventions for sarcopenia and the impact on OS.

原文英語
文章編號6911
頁(從 - 到)6911
期刊Scientific Reports
卷13
發行號1
DOIs
出版品狀態已出版 - 27 04 2023
對外發佈是

文獻附註

© 2023. The Author(s).

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy」主題。共同形成了獨特的指紋。

引用此